Patents by Inventor Kristen Jean Vallieu
Kristen Jean Vallieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959108Abstract: The present invention provides engineered protease polypeptides and compositions thereof. The engineered protease polypeptides have been optimized to provide improved activity, improved thermostability, protease stability, autolytic stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered protease polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered protease polypeptides, as well as methods for making the engineered polynucleotides and protease polypeptides.Type: GrantFiled: August 27, 2021Date of Patent: April 16, 2024Assignees: Codexis, Inc., Societe des Produits Nestle S.A.Inventors: Chinping Chng, Nikki Dellas, Ravi David Garcia, Moulay Hicham Alaoui Ismaili, Kristen Jean Vallieu, Kerryn McCluskie
-
Publication number: 20240018504Abstract: The present invention provides engineered leucine decarboxylase (LDC) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered leucine decarboxylase (LDC) polypeptides. In some embodiments, the engineered LDC polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis, and/or increased tolerance to low pH environments. In some embodiments, the engineered LDC polypeptides are optimized to provide improved storage stability. The present invention also provides methods for the use of the compositions comprising the engineered LDC polypeptides for therapeutic and industrial purposes.Type: ApplicationFiled: August 2, 2023Publication date: January 18, 2024Inventors: Joyce Liu, Leann Quertinmont Teadt, Nikki Dellas, Stephan Jenne, Faye Loan Du, Kristen Jean Vallieu, Kerryn McCluskie
-
Publication number: 20230277635Abstract: The present invention provides engineered leucine decarboxylase (LDC) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered leucine decarboxylase polypeptides. In some embodiments, the engineered leucine decarboxylase polypeptides display enhanced catalytic activity, as well as reduced sensitivity to proteolysis, and/or increased tolerance to low pH environments. In some embodiments, the engineered leucine decarboxylase polypeptides are optimized to provide improved storage stability. The present invention also provides methods for the use of the compositions comprising the engineered leucine decarboxylase polypeptides for therapeutic and industrial purposes.Type: ApplicationFiled: November 1, 2022Publication date: September 7, 2023Inventors: Jonathan Benjamin Asfaha, Subhamoy Das, Faye Loan Du, Stephan Jenne, Nikki D. Kruse, Joyce Liu, Kerryn McCluskie, Roasa Mehmood, Adam P. Silverman, Kristen Jean Vallieu
-
Publication number: 20220403362Abstract: The present invention provides engineered methionine gamma lyase polypeptides and compositions thereof. The engineered methionine gamma lyase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The present invention also relates to the use of the compositions comprising the engineered methionine gamma lyase polypeptides for therapeutic purposes.Type: ApplicationFiled: May 19, 2022Publication date: December 22, 2022Inventors: Kierra Aleece Franklin, Stephanie Sue Galanie, Gjalt W. Huisman, Nikki D. Kruse, Kerryn McCluskie, Vesna Mitchell, Leann Quertinmont Teadt, Kristen Jean Vallieu
-
Publication number: 20220356458Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: ApplicationFiled: July 22, 2022Publication date: November 10, 2022Inventors: William Casey Hallows, Kristen Jean Vallieu, Nikki Dellas, Yu Zhu, Judy Victoria Antonio Viduya, Chinping Chng, Antoinette Sero, Gjalt W. Huisman, Rachel Cathleen Botham, Moulay Hicham Alaoui Ismaili
-
Patent number: 11427813Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: GrantFiled: December 19, 2019Date of Patent: August 30, 2022Assignee: Codexis, Inc.Inventors: William Casey Hallows, Kristen Jean Vallieu, Nikki Dellas, Yu Zhu, Judy Victoria Antonio Viduya, Chinping Chng, Antoinette Sero, Gjalt W. Huisman, Rachel Cathleen Botham, Moulay Hicham Alaoui Ismaili
-
Publication number: 20220090039Abstract: The present invention provides engineered protease polypeptides and compositions thereof. The engineered protease polypeptides have been optimized to provide improved activity, improved thermostability, protease stability, autolytic stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered protease polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered protease polypeptides, as well as methods for making the engineered polynucleotides and protease polypeptides.Type: ApplicationFiled: August 27, 2021Publication date: March 24, 2022Inventors: Chinping Chng, Nikki Dellas, Ravi David Garcia, Moulay Hicham Alaoui Ismaili, Kristen Jean Vallieu, Kerryn McCluskie
-
Publication number: 20210269789Abstract: The present invention provides engineered branched chain ketoacid decarboxylase (KdcA) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered branched chain ketoacid decarboxylase (KdcA) polypeptides. In some embodiments, the engineered KdcA polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. The present invention also provides methods for the use of the compositions comprising the engineered KdcA polypeptides for therapeutic and industrial purposes.Type: ApplicationFiled: June 27, 2019Publication date: September 2, 2021Inventors: Xiang Yi, Nikki Dellas, James Nicholas Riggins, Chinping Chng, Nicholas J. Agard, Kristen Jean Vallieu, Gjalt W. Huisman
-
Publication number: 20210269787Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: ApplicationFiled: February 26, 2021Publication date: September 2, 2021Inventors: William Casey Hallows, Nikki Dellas, Yu Zhu, Judy Victoria Antonio Viduya, Chinping Chng, Antoinette Sero, Rachel Cathleen Botham, David William Homan, Moulay Hicham Alaoui Ismaili, Jonathan Vroom, Adam P. Silverman, Kristen Jean Vallieu, Charu Shukla Reddy, Kerryn McCluskie
-
Publication number: 20210238575Abstract: The present invention provides engineered leucine decarboxylase (LDC) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered leucine decarboxylase (LDC) polypeptides. In some embodiments, the engineered LDC polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis, and/or increased tolerance to low pH environments. In some embodiments, the engineered LDC polypeptides are optimized to provide improved storage stability. The present invention also provides methods for the use of the compositions comprising the engineered LDC polypeptides for therapeutic and industrial purposes.Type: ApplicationFiled: February 3, 2021Publication date: August 5, 2021Inventors: Joyce Liu, Leann Quertinmont Teadt, Nikki Dellas, Stephan Jenne, Faye Loan Du, Kristen Jean Vallieu, Kerryn McCluskie
-
Publication number: 20210062168Abstract: The present invention provides engineered lipase polypeptides and compositions thereof. The engineered lipase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered lipase polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered lipase polypeptides, as well as methods for making the engineered polynucleotides and lipase polypeptides.Type: ApplicationFiled: August 28, 2020Publication date: March 4, 2021Inventors: Chinping Chng, William Casey Hallows, Judy Victoria Antonio Viduya, Nikki Dellas, Stephanie Sue Galanie, Kristen Jean Vallieu
-
Publication number: 20200199563Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: ApplicationFiled: December 19, 2019Publication date: June 25, 2020Inventors: William Casey Hallows, Kristen Jean Vallieu, Nikki Dellas, Yu Zhu, Judy Victoria Antonio Viduya, Chinping Chng, Antoinette Sero, Gjalt W. Huisman, Rachel Cathleen Botham